These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Clinical efficacy of micafungin for chronic pulmonary aspergillosis. Izumikawa K, Ohtsu Y, Kawabata M, Takaya H, Miyamoto A, Sakamoto S, Kishi K, Tsuboi E, Homma S, Yoshimura K. Med Mycol; 2007 May; 45(3):273-8. PubMed ID: 17464848 [Abstract] [Full Text] [Related]
23. Invasive candidiasis in cancer patients: observations from a randomized clinical trial. DiNubile MJ, Hille D, Sable CA, Kartsonis NA. J Infect; 2005 Jun; 50(5):443-9. PubMed ID: 15907554 [Abstract] [Full Text] [Related]
27. Clinical efficacy and tolerability of caspofungin in a renal transplant patient with Aspergillus flavus lung infection: case report. Pasticci MB, Barchiesi F, Fallani S, Palladino N, Lapalorcia LM, Gubbiotti M, Cozzari M, Novelli A, Baldelli F. J Chemother; 2006 Oct; 18(5):549-53. PubMed ID: 17127234 [Abstract] [Full Text] [Related]
28. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. Walsh TJ, Teppler H, Donowitz GR, Maertens JA, Baden LR, Dmoszynska A, Cornely OA, Bourque MR, Lupinacci RJ, Sable CA, dePauw BE. N Engl J Med; 2004 Sep 30; 351(14):1391-402. PubMed ID: 15459300 [Abstract] [Full Text] [Related]
29. Caspofungin as first-line therapy for the treatment of invasive aspergillosis after thoracic organ transplantation. Groetzner J, Kaczmarek I, Wittwer T, Strauch J, Meiser B, Wahlers T, Daebritz S, Reichart B. J Heart Lung Transplant; 2008 Jan 30; 27(1):1-6. PubMed ID: 18187079 [Abstract] [Full Text] [Related]
30. Assessing the antifungal activity and toxicity profile of amphotericin B lipid complex (ABLC; Abelcet) in combination with caspofungin in experimental systemic aspergillosis. Sivak O, Bartlett K, Risovic V, Choo E, Marra F, Batty DS, Wasan KM. J Pharm Sci; 2004 Jun 30; 93(6):1382-9. PubMed ID: 15124198 [Abstract] [Full Text] [Related]
33. Does combination of lipid formulation of amphotericin B and echinocandins improve outcome of invasive aspergillosis in hematological malignancy patients? Mihu CN, Kassis C, Ramos ER, Jiang Y, Hachem RY, Raad II. Cancer; 2010 Nov 15; 116(22):5290-6. PubMed ID: 20665889 [Abstract] [Full Text] [Related]
34. Caspofungin plus posaconazole as salvage therapy of invasive fungal infections in immunocompromised patients. Lellek H, Waldenmaier D, Dahlke J, Ayuk FA, Wolschke C, Kröger N, Zander AR. Mycoses; 2011 Jan 15; 54 Suppl 1():39-44. PubMed ID: 21126271 [Abstract] [Full Text] [Related]
36. Randomised, multicentre trial of micafungin vs. an institutional standard regimen for salvage treatment of invasive aspergillosis. Cornely OA, Meems L, Herbrecht R, Viscoli C, van Amsterdam RG, Ruhnke M. Mycoses; 2015 Jan 15; 58(1):58-64. PubMed ID: 25530265 [Abstract] [Full Text] [Related]
37. Efficacy of Abelcet and caspofungin, alone or in combination, against CNS aspergillosis in a murine model. Imai J, Singh G, Fernandez B, Clemons KV, Stevens DA. J Antimicrob Chemother; 2005 Jul 15; 56(1):166-71. PubMed ID: 15917284 [Abstract] [Full Text] [Related]
38. Experimental systemic murine aspergillosis: treatment with polyene and caspofungin combination and G-CSF. Sionov E, Mendlovic S, Segal E. J Antimicrob Chemother; 2005 Sep 15; 56(3):594-7. PubMed ID: 16006446 [Abstract] [Full Text] [Related]